To determine whether long-term
oral administration of UFT, a combination of
5-fluorouracil and
uracil, in addition to conventional
estrogen therapy improved the response and survival of the patients with advanced stage D2 prostate
adenocarcinoma, a randomized prospective study was performed with either
estrogen alone (
Honvan 200 mg/day or presexol 1 mg/day: group A) or
estrogen plus UFT (400 mg/day:group B). This study comprises 34 newly diagnosed patients with poorly differentiated prostatic
adenocarcinoma (18 patients in group A and 16 in group B). Survival from all causes of death or
cancer-specific death were compared using Kaplan-Meier actual methods among the patients separated by histological composition of
tumors analyzed WHO histologic patterns, score of extent of disease (EOD), and with or without normalization of serum PSA or PAP levels
after treatment. Although combination
therapy with UFT against overall survival was effective without statistical significance, better survival in this group than the patients treatment with
estrogen alone assessed among the patients whose
tumor contained more than 70% of medullary and/or column-cord histological components. The survivals among the patients with EOD score 3 and whose serum PSA or PAP levels did not lead to decrease within normal levels
after treatment were also better in group B than in group A. These findings suggest the validity of the combination
therapy with UFT in addition to
estrogen against highly advanced
prostatic cancer patients whose
tumor composed of abundant non-
hormone-refractor histological components.